Enrolled
Underlined text would be added to current law. Struck-through text would be removed.
| By: Parker | S.R. No. 703 |
| SENATE RESOLUTION | ||
| BE IT RESOLVED by the Senate of the State of Texas, 89th | ||
| Legislature, Regular Session, 2025, That Senate Rule 12.03 be | ||
| suspended in part as provided by Senate Rule 12.08 to enable the | ||
| conference committee appointed to resolve the differences on | ||
| Senate Bill 2308 (the establishment of a consortium to conduct | ||
| United States Food and Drug Administration's drug development | ||
| clinical trials with ibogaine to secure the administration's | ||
| approval of the medication's use for treatment of opioid use | ||
| disorder, co-occurring substance use disorder, and any other | ||
| neurological or mental health conditions for which ibogaine | ||
| demonstrates efficacy and to the administration of that | ||
| treatment) to consider and take action on the following matters: | ||
| (1) Senate Rule 12.03(2) is suspended to permit the | ||
| committee to omit text not in disagreement by omitting in | ||
| proposed SECTION 1 of the bill added Section 491.001(2), Health | ||
| and Safety Code. The omitted text reads: | ||
| (2) "Executive commissioner" means the executive | ||
| commissioner of the Health and Human Services Commission. | ||
| Explanation: The change is necessary to remove a | ||
| definition that no longer appears in added Chapter 491, Health | ||
| and Safety Code. | ||
| (2) Senate Rule 12.03(4) is suspended to permit the | ||
| committee to add text on a matter not included in either the house | ||
| or senate version of the bill in proposed SECTION 1 of the bill, | ||
| by adding Sections 491.001(2), (3), (4), and (6), Health and | ||
| Safety Code, to read as follows: | ||
| (2) "Comptroller" means the comptroller of public | ||
| accounts. | ||
| (3) "Drug developer" means a pharmaceutical | ||
| company, biotechnology company, or contract development and | ||
| manufacturing organization engaged in drug development and | ||
| manufacturing. | ||
| (4) "Hospital" has the meaning assigned by Section | ||
| 241.003. | ||
| (6) "Institution of higher education" has the | ||
| meaning assigned by Section 61.003, Education Code. | ||
| Explanation: The change is necessary to define | ||
| "comptroller," "drug developer," "hospital," and "institution of | ||
| higher education" for purposes of added Chapter 491, Health and | ||
| Safety Code. | ||
| (3) Senate Rule 12.03(2) is suspended to permit the | ||
| committee to omit text not in disagreement in proposed SECTION 1 | ||
| of the bill by omitting added Sections 491.002 and 491.003, | ||
| Health and Safety Code. The omitted text reads: | ||
| Sec. 491.002. RULES. The executive commissioner shall | ||
| adopt rules necessary to administer this chapter. | ||
| Sec. 491.003. ESTABLISHMENT OF GRANT PROGRAM. The | ||
| commission shall establish and administer a grant program to fund | ||
| a public-private partnership program that will pay for the costs | ||
| of the United States Food and Drug Administration's drug | ||
| development trials with ibogaine to secure the administration's | ||
| approval as a medication for treatment of opioid use disorder, | ||
| co-occurring substance use disorder, and any other neurological | ||
| or mental health conditions for which ibogaine demonstrates | ||
| efficacy. | ||
| Explanation: The change is necessary to eliminate | ||
| rulemaking authority and remove a grant program. | ||
| (4) Senate Rule 12.03(4) is suspended to permit the | ||
| committee to add text on a matter not included in either the house | ||
| or senate version of the bill in proposed SECTION 1 of the bill, | ||
| by adding a heading for added Subchapter B, Chapter 491, Health | ||
| and Safety Code, to read as follows: | ||
| SUBCHAPTER B. DRUG DEVELOPMENT OF IBOGAINE TREATMENT | ||
| Explanation: The change is necessary for better | ||
| organization of added Chapter 491, Health and Safety Code. | ||
| (5) Senate Rule 12.03(4) is suspended to permit the | ||
| committee to add text on a matter not included in either the house | ||
| or senate version of the bill in proposed SECTION 1 of the bill, | ||
| by adding Sections 491.051 and 491.052, Health and Safety Code, | ||
| to read as follows: | ||
| Sec. 491.051. ESTABLISHMENT OF CONSORTIUM. (a) A | ||
| consortium may be established under this section and apply for | ||
| commission selection under this subchapter to conduct drug | ||
| development clinical trials with ibogaine and secure the United | ||
| States Food and Drug Administration's approval of ibogaine as a | ||
| medication for the treatment of: | ||
| (1) opioid use disorder; | ||
| (2) co-occurring substance use disorder; and | ||
| (3) any other neurological or mental health | ||
| condition for which ibogaine demonstrates efficacy. | ||
| (b) A consortium established under this section must | ||
| include one or more of each of the following entities: | ||
| (1) a drug developer; | ||
| (2) an institution of higher education; and | ||
| (3) a hospital. | ||
| Sec. 491.052. LEAD INSTITUTION; ADMINISTRATION; | ||
| PERSONNEL. (a) A consortium established under this subchapter | ||
| shall select a lead institution of higher education from among | ||
| the consortium's members to represent the consortium and perform | ||
| administrative functions under this subchapter, including | ||
| contracting with and reporting to the commission as required by | ||
| this subchapter. | ||
| (b) A consortium selected by the commission under this | ||
| subchapter may employ personnel, including clinical, | ||
| administrative, and data management personnel, necessary to | ||
| support any consortium member's activities related to drug | ||
| development clinical trials conducted under this subchapter. | ||
| Explanation: The change is necessary to allow formation | ||
| of a consortium for the conduct of certain drug development | ||
| clinical trials, to secure United States Food and Drug | ||
| Administration's approval for certain medical treatments, and to | ||
| allow the consortium to select a lead institution and employ | ||
| necessary personnel. | ||
| (6) Senate Rule 12.03(2) is suspended to permit the | ||
| committee to omit text not in disagreement in proposed SECTION 1 | ||
| of the bill by omitting the heading and Subsections (a) and (c) of | ||
| added Section 491.004, Health and Safety Code. The omitted text | ||
| reads: | ||
| Sec. 491.004. APPLICATION. (a) The commission shall | ||
| prepare and issue a notice of funding opportunity to solicit | ||
| applications for the grant program established under this | ||
| subchapter. | ||
| (c) The commission shall: | ||
| (1) make available the application required under | ||
| this section; and | ||
| (2) announce a period of not less than 90 days | ||
| during which applicants may submit an application under this | ||
| subchapter. | ||
| Explanation: The change is necessary to remove an | ||
| application process for a removed grant program. | ||
| (7) Senate Rule 12.03(4) is suspended to permit the | ||
| committee to add text on a matter not included in either the house | ||
| or senate version of the bill in proposed SECTION 1 of the bill, | ||
| by adding a heading and Subsection (a) for Section 491.053, | ||
| Health and Safety Code, to read as follows: | ||
| Sec. 491.053. CONSORTIUM PROPOSAL. (a) The lead | ||
| institution of higher education of a consortium shall submit to | ||
| the commission a proposal and request for funding on behalf of | ||
| the consortium for purposes of conducting ibogaine drug | ||
| development clinical trials in accordance with this subchapter. | ||
| Explanation: The change is necessary to require a | ||
| consortium formed under added Chapter 491, Health and Safety | ||
| Code, to submit to the Health and Human Services Commission a | ||
| proposal for selection to conduct a drug development clinical | ||
| trial under that chapter. | ||
| (8) Senate Rules 12.03(1), (2), and (3) are suspended to | ||
| permit the committee to change, alter, or amend text not in | ||
| disagreement, omit text not in disagreement, and add text on a | ||
| matter not in disagreement in proposed SECTION 1 of the bill, by | ||
| adding Section 491.053(b), Health and Safety Code, to read as | ||
| follows: | ||
| (b) A proposal submitted under Subsection (a) must | ||
| provide: | ||
| (1) the identity of all consortium members; | ||
| (2) a detailed description of the planned strategy | ||
| for obtaining approval for the drug development clinical trials | ||
| from the United States Food and Drug Administration; | ||
| (3) a detailed drug development clinical trial | ||
| design that includes: | ||
| (A) a description of the composition of the | ||
| consortium's drug development clinical trial team and the | ||
| expertise of the team members; | ||
| (B) a drug development clinical trial | ||
| participant recruitment plan; | ||
| (C) patient screening criteria and cardiac | ||
| safety protocols; | ||
| (D) administration protocols; | ||
| (E) an aftercare and post-acute treatment | ||
| support plan; and | ||
| (F) a data integrity plan; | ||
| (4) a detailed plan to seek a breakthrough therapy | ||
| designation for ibogaine from the United States Food and Drug | ||
| Administration under 21 U.S.C. Section 356; | ||
| (5) a proposal to recognize this state's commercial | ||
| interest in all intellectual property that may be generated over | ||
| the course of the drug development clinical trials, including: | ||
| (A) the treatment that is the subject of the | ||
| trials; | ||
| (B) administration protocols; | ||
| (C) treatment models or techniques; and | ||
| (D) technology used in the trials; | ||
| (6) a plan to establish a corporate presence in this | ||
| state and to promote and maintain ibogaine-related biomedical | ||
| research, development, treatment, manufacturing, and | ||
| distribution in this state; | ||
| (7) a plan to secure third-party payor approval for | ||
| ibogaine treatment following approval by the United States Food | ||
| and Drug Administration through: | ||
| (A) private insurers; | ||
| (B) Medicare; | ||
| (C) Medicaid; and | ||
| (D) the TRICARE program of the United States | ||
| Department of Defense; | ||
| (8) a plan to ensure ibogaine treatment access to | ||
| uninsured individuals following approval by the United States | ||
| Food and Drug Administration; | ||
| (9) a plan to train and credential medical providers | ||
| to administer ibogaine treatment according to developed clinical | ||
| standards; and | ||
| (10) financial disclosures that verify the | ||
| consortium's capacity to fully match state funding with funds | ||
| received from non-state sources. | ||
| Explanation: The change is necessary to specify the | ||
| information required for submission of a proposal under Section | ||
| 491.053, Health and Safety Code, and selection to perform drug | ||
| development clinical trials under added Chapter 491, Health and | ||
| Safety Code. | ||
| (9) Senate Rule 12.03(2) is suspended to permit the | ||
| committee to omit text not in disagreement in proposed SECTION 1 | ||
| of the bill by omitting added Section 491.005, Health and Safety | ||
| Code. The omitted text reads: | ||
| Sec. 491.005. SELECTION COMMITTEE. (a) The commission | ||
| shall create a selection committee and select the number of | ||
| members. The committee must be composed of: | ||
| (1) subject matter experts; | ||
| (2) philanthropic partners; and | ||
| (3) legislative designees. | ||
| (b) The selection committee shall review applications, | ||
| communicate supplemental inquiries to applicants, and recommend | ||
| to the commission the best applicants to conduct the drug | ||
| development trials. | ||
| (c) The commission shall consider the recommendations of | ||
| the selection committee in selecting the applicant to conduct the | ||
| ibogaine drug development trial. | ||
| Explanation: The change is necessary to remove the | ||
| selection committee. | ||
| (10) Senate Rule 12.03(4) is suspended to permit the | ||
| committee to add text on a matter not included in either the house | ||
| or senate version of the bill in proposed SECTION 1 of the bill, | ||
| by adding Sections 491.054 and 491.055, Health and Safety Code, | ||
| to read as follows: | ||
| Sec. 491.054. COMMISSION SELECTION. The commission, in | ||
| the commission's sole discretion, shall select a consortium | ||
| established in accordance with Section 491.051 for the purpose of | ||
| conducting ibogaine drug development clinical trials under this | ||
| subchapter. | ||
| Sec. 491.055. CONTRACT WITH LEAD INSTITUTION. (a) As | ||
| soon as practicable after selecting a consortium to conduct | ||
| ibogaine drug development clinical trials under Section 491.054, | ||
| the commission shall enter into an interagency contract, as | ||
| provided by Chapter 771, Government Code, with the lead | ||
| institution of higher education of the selected consortium to | ||
| provide funding to implement the consortium's proposed ibogaine | ||
| drug development clinical trials. | ||
| (b) The interagency contract described by Subsection (a) | ||
| must specify: | ||
| (1) the goals and objectives of the proposed | ||
| ibogaine drug development clinical trials; | ||
| (2) the proposed budget; | ||
| (3) the timeline for completing the proposed | ||
| objectives; | ||
| (4) the for-profit, nonprofit, or public benefit | ||
| corporate entities collaborating with the consortium in the drug | ||
| development clinical trials under this subchapter; | ||
| (5) the percentage of the revenue arising from the | ||
| drug development clinical trials to be paid to the state; and | ||
| (6) any other information required by the | ||
| commission. | ||
| (c) As soon as practicable after entering into an | ||
| interagency contract under Subsection (a), the commission shall | ||
| report the existence of the contract to the legislature. | ||
| (d) The commission may not disburse funds to or for a | ||
| selected consortium under the interagency contract described by | ||
| Subsection (a) until the consortium receives and the commission | ||
| verifies the receipt of matching funds from sources other than | ||
| the state. | ||
| Explanation: The change is necessary to allow the Health | ||
| and Human Services Commission to select a consortium established | ||
| under added Chapter 491, Health and Safety Code, for the purpose | ||
| of conducting drug development clinical trials under that | ||
| chapter, to require the commission to enter into an interagency | ||
| contract with the consortium for the conduct of those trials, and | ||
| to regulate the contract provisions and the disbursement of funds | ||
| to the selected consortium. | ||
| (11) Senate Rules 12.03(1) and (3) are suspended to | ||
| permit the committee to change, alter, or amend text not in | ||
| disagreement and add text on a matter not in disagreement in | ||
| proposed SECTION 1 of the bill, by adding Section 491.056, Health | ||
| and Safety Code, to read as follows: | ||
| Sec. 491.056. INVESTIGATIONAL NEW DRUG APPLICATION. On | ||
| the commission's notification that a consortium is selected to | ||
| conduct the drug development clinical trials under this | ||
| subchapter, a drug developer or hospital member of the selected | ||
| consortium or the lead institution of higher education of the | ||
| consortium, as specified by written agreement of the consortium | ||
| members, shall, as soon as practicable: | ||
| (1) submit an investigational new drug (IND) | ||
| application to the United States Food and Drug Administration in | ||
| accordance with 21 C.F.R. Part 312; and | ||
| (2) seek a breakthrough therapy designation for | ||
| ibogaine from the United States Food and Drug Administration | ||
| under 21 U.S.C. Section 356. | ||
| Explanation: The change is necessary to allow certain | ||
| members of a consortium established under added Chapter 491, | ||
| Health and Safety Code, to apply for an investigational new drug | ||
| application with the United States Food and Drug Administration | ||
| and to seek from the administration a breakthrough therapy | ||
| designation for certain treatments. | ||
| (12) Senate Rule 12.03(4) is suspended to permit the | ||
| committee to add text on a matter not included in either the house | ||
| or senate version of the bill in proposed SECTION 1 of the bill, | ||
| by adding Section 491.057, Health and Safety Code, to read as | ||
| follows: | ||
| Sec. 491.057. DRUG DEVELOPMENT CLINICAL TRIAL | ||
| SITES. For purposes of conducting a drug development clinical | ||
| trial under this subchapter, only an institution of higher | ||
| education or a hospital may serve as a trial site. | ||
| Explanation: The change is necessary to specify which | ||
| members of a consortium established under added Chapter 491, | ||
| Health and Safety Code, may serve as a drug development clinical | ||
| trial site under that chapter. | ||
| (13) Senate Rule 12.03(2) is suspended to permit the | ||
| committee to omit text not in disagreement in proposed SECTION 1 | ||
| of the bill by omitting added Sections 491.007 and 491.008, | ||
| Health and Safety Code. The omitted text reads: | ||
| Sec. 491.007. ESTABLISHMENT OF DRUG DEVELOPMENT TRIAL | ||
| SITES. On approval of the applicant's investigational new drug | ||
| application by the United States Food and Drug Administration, | ||
| the commission shall, in consultation with the applicant, | ||
| establish drug development trial sites that must be equipped and | ||
| staffed to provide cardiac intensive care services to patients. | ||
| Sec. 491.008. CONDUCTING DRUG DEVELOPMENT TRIAL. (a) As | ||
| soon as practicable after drug development trial sites are | ||
| established under Section 491.007, the applicant shall begin a | ||
| drug development trial to administer treatment with ibogaine. | ||
| (b) The commission, in consultation with the selection | ||
| committee under Section 491.005, shall select an institutional | ||
| review board with a presence in this state to oversee and verify | ||
| the drug development trial research activity for scientific | ||
| validation and authentication under the requirements of the | ||
| United States Food and Drug Administration. | ||
| (c) The applicant shall request the designation under 21 | ||
| U.S.C. Section 356 during the drug development trial if the | ||
| ibogaine treatment is demonstrating efficacy. | ||
| Explanation: The change is necessary to remove | ||
| requirements relating to drug development trial sites and the | ||
| conduct of a drug development trial. | ||
| (14) Senate Rules 12.03(1), (2), and (4) are suspended to | ||
| permit the committee to change, alter, or amend text not in | ||
| disagreement, omit text on a matter not in disagreement, and add | ||
| text on a matter not included in either the house or senate | ||
| version of the bill in proposed SECTION 1 of the bill, by adding | ||
| Section 491.058, Health and Safety Code, to read as follows: | ||
| Sec. 491.058. FUNDING; DISBURSEMENT BY COMMISSION. (a) | ||
| The commission and consortium members may solicit and accept | ||
| gifts, grants, and donations of any kind received from sources | ||
| other than the state for purposes of funding drug development | ||
| clinical trials under this subchapter. | ||
| (b) Disbursements of funds by the commission may be made | ||
| incrementally based on the completion of clearly defined | ||
| objectives as negotiated in the contract described by Section | ||
| 491.055, including verifiable documentation demonstrating the | ||
| efficient expenditure of both state and matching funds. | ||
| Explanation: The change is necessary to clarify that | ||
| matching funds provided by a consortium established under added | ||
| Chapter 491, Health and Safety Code, must come from sources other | ||
| than the state, and to add accountability requirements. | ||
| (15) Senate Rule 12.03(2) is suspended to permit the | ||
| committee to omit text not in disagreement in proposed SECTION 1 | ||
| of the bill by omitting added Section 491.009(b), Health and | ||
| Safety Code. The omitted text reads: | ||
| (b) An applicant selected to perform a drug development | ||
| trial under this subchapter shall contribute toward the cost of | ||
| developing the ibogaine treatment an amount of money that is at | ||
| least equal to the amount of money that the applicant received in | ||
| the form of a grant from the commission. | ||
| Explanation: The change is necessary to eliminate | ||
| duplicative and conflicting provisions relating to matching | ||
| funds. | ||
| (16) Senate Rule 12.03(4) is suspended to permit the | ||
| committee to add text on a matter not included in either the house | ||
| or senate version of the bill in proposed SECTION 1 of the bill, | ||
| by adding Sections 491.059, 491.060, and 491.061, Health and | ||
| Safety Code, to read as follows: | ||
| Sec. 491.059. REPORTING REQUIREMENTS. (a) A consortium | ||
| selected to conduct ibogaine drug development clinical trials | ||
| shall quarterly prepare and submit to the commission: | ||
| (1) a report on the progress of the drug development | ||
| clinical trials conducted under this subchapter; and | ||
| (2) a financial status report, including | ||
| information to verify expenditures of state funds and required | ||
| matching funds. | ||
| (b) The commission shall submit a report to the | ||
| legislature on the progress of the drug development clinical | ||
| trials conducted under this subchapter not later than December 1 | ||
| of each year. | ||
| Sec. 491.060. ALLOCATION OF REVENUE ATTRIBUTABLE TO | ||
| INTELLECTUAL PROPERTY AND OTHER RIGHTS. (a) The revenue | ||
| attributable to all intellectual property rights and other | ||
| commercial rights arising from drug development clinical trials | ||
| conducted by a consortium under this subchapter during the period | ||
| for which the trials are funded and any following period of | ||
| commercialization shall be allocated as follows: | ||
| (1) not less than 20 percent to the state as | ||
| specified in the contract under Section 491.055; and | ||
| (2) the remainder to the members of the consortium | ||
| in the amounts specified by written agreement of the members. | ||
| (b) For purposes of this section, intellectual property | ||
| rights and other commercial rights arising from the drug | ||
| development clinical trials conducted under this subchapter | ||
| include any of the following as related to the trials: | ||
| (1) intellectual property, technology, and | ||
| inventions; | ||
| (2) patents, trademarks, and licenses; | ||
| (3) proprietary and confidential information; | ||
| (4) trade secrets, data, and databases; | ||
| (5) tools, methods, and processes; | ||
| (6) treatment models or techniques; | ||
| (7) administration protocols; and | ||
| (8) works of authorship. | ||
| Sec. 491.061. USE OF STATE REVENUE. (a) The comptroller | ||
| shall deposit the revenue received under Section 491.060 to the | ||
| credit of the general revenue fund. | ||
| (b) Of the amount deposited under Subsection (a), 25 | ||
| percent may be appropriated only to programs that assist veterans | ||
| in this state. | ||
| (c) The comptroller shall develop accounting procedures | ||
| for the purpose of implementing this section. | ||
| Explanation: The change is necessary to establish | ||
| reporting requirements for a consortium established under added | ||
| Chapter 491, Health and Safety Code, and to clarify the | ||
| allocation of revenues attributable to certain property rights | ||
| under that chapter. | ||
| (17) Senate Rule 12.03(4) is suspended to permit the | ||
| committee to add text on a matter not included in either the house | ||
| or senate version of the bill in proposed SECTION 2 of the bill, | ||
| by adding Subsection (b) to read as follows: | ||
| (b) The Health and Human Services Commission shall begin | ||
| accepting proposals from consortiums under Chapter 491, Health | ||
| and Safety Code, as added by this Act, not later than the 60th day | ||
| after the effective date of this Act. | ||
| Explanation: The change is necessary to require the | ||
| Health and Human Services Commission to begin accepting | ||
| proposals from consortiums under added Chapter 491, Health and | ||
| Safety Code, by a certain date. | ||
| _______________________________ | ||
| President of the Senate | ||
| I hereby certify that the | ||
| above Resolution was adopted by | ||
| the Senate on May 31, 2025, by the | ||
| following vote: Yeas 31, Nays 0. | ||
| _______________________________ | ||
| Secretary of the Senate |
Official text from the Texas Legislature. Formatting has been adapted for reading on Ratifi.